FY2026 Earnings Estimate for CVRx Issued By William Blair

CVRx, Inc. (NASDAQ:CVRX) – Research analysts at William Blair issued their FY2026 earnings per share estimates for shares of CVRx in a report issued on Friday, December 13th. William Blair analyst M. Andrew forecasts that the company will post earnings per share of ($1.91) for the year. The consensus estimate for CVRx’s current full-year earnings is ($2.62) per share.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). The company had revenue of $13.37 million for the quarter, compared to analysts’ expectations of $13.28 million. CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. During the same quarter last year, the business posted ($0.43) EPS.

Several other brokerages have also issued reports on CVRX. Craig Hallum boosted their target price on CVRx from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Piper Sandler restated an “overweight” rating and issued a $16.00 price objective (up from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $14.00 target price on shares of CVRx in a research report on Wednesday, October 23rd. Lake Street Capital boosted their price target on shares of CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group upped their price target on shares of CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, CVRx presently has an average rating of “Moderate Buy” and an average price target of $16.67.

CVRx Trading Down 4.3 %

NASDAQ:CVRX opened at $12.83 on Monday. The firm’s 50 day moving average is $12.60 and its 200 day moving average is $10.45. CVRx has a 12 month low of $6.40 and a 12 month high of $33.13. The stock has a market capitalization of $311.31 million, a PE ratio of -4.75 and a beta of 1.20. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76.

Institutional Investors Weigh In On CVRx

Institutional investors and hedge funds have recently modified their holdings of the company. PDT Partners LLC bought a new stake in CVRx during the 3rd quarter worth approximately $543,000. International Assets Investment Management LLC bought a new position in CVRx in the 3rd quarter valued at $338,000. Bank of New York Mellon Corp grew its position in shares of CVRx by 30.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,191 shares of the company’s stock valued at $446,000 after purchasing an additional 8,741 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of CVRx in the second quarter worth $218,000. Finally, Rhumbline Advisers raised its position in shares of CVRx by 28.8% in the second quarter. Rhumbline Advisers now owns 17,260 shares of the company’s stock worth $207,000 after buying an additional 3,863 shares in the last quarter. 75.27% of the stock is owned by hedge funds and other institutional investors.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.